Immunoglobulin Market Report by Product, Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, and Others), Mode of Delivery, and Region 2024-2032
¼¼°èÀÇ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ±Ô¸ð´Â 2023³â 157¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 249¾ï ´Þ·¯¿¡ À̸£¸ç 2024³â°ú 2032³â »çÀÌ¿¡ 5.1%ÀÇ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.
Ç×ü·Îµµ ¾Ë·ÁÁø ¸é¿ª±Û·ÎºÒ¸°Àº Ç÷Àå ¶Ç´Â ¹éÇ÷±¸(WBC)¿¡ ÀÇÇØ »ý»êµÇ´Â ´ç´Ü¹éÁú ºÐÀÚÀÇ ±ºÀ» ¸»ÇÕ´Ï´Ù. ¸é¿ª±Û·ÎºÒ¸°Àº ÀϹÝÀûÀ¸·Î Ç÷û ¹× ¸é¿ª°èÀÇ ¼¼Æ÷ ³»¿¡ Á¸ÀçÇϸç, ¹ÚÅ׸®¾Æ³ª ¹ÙÀÌ·¯½º µîÀÇ Ç׿øÀ» ¸íÈ®ÇÏ°Ô ÀνÄÇÏ°í °áÇÕÇϰí, ±× ÆÄ±«¸¦ µ½´Â °ÍÀ¸·Î Ç×ü·Î¼ ±â´ÉÇÕ´Ï´Ù. ÀÌ °Ë»ç´Â Àǻ簡 ¸é¿ª °áÇÌ, ¾Ë·¹¸£±â, ¼Ò¾Æ Ư¹ß¼º °üÀý¿°, ³¶Ã¢, ¼¿¸®¾Çº´°ú °°ÀºÀÚ°¡ ¸é¿ª ÁúȯÀ» Áø´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇöÀç, ¸é¿ª±Û·ÎºÒ¸°Àº »ý¹°ÇÐÀû Ư¡, ±¸Á¶, Ç¥Àû ƯÀ̼º, ºÐÆ÷ÀÇ Â÷ÀÌ·Î ÀÎÇØ ´Ù¾çÇÑ Å¬·¡½º¸¦ ¼¼°è¿¡¼ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸é¿ª±Û·ÎºÒ¸° ½ÃÀå µ¿Çâ :
±Þ¼ÓÇÑ µµ½ÃÈ¿Í ¹Ù»Û ÀÏÁ¤À¸·Î ÀÎÇØ °³ÀÎ °£¿¡ ÆÐ½ºÆ® Ǫµå ¼Òºñ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À̰ÍÀº ¾É±â ½¬¿î ¶óÀÌÇÁ ½ºÅ¸Àϰú ´Ù¹ß¼º °ñ¼öÁ¾, ¿Ðµ§ ½´Æ®·½ ¸¶Å©·Î ±Û·ÎºÒ¸° Ç÷Áõ,ÀÚ°¡ ¸é¿ª Áúȯ µîÀÇ º´¸®ÇÐ Àû ȯÀÚ Áõ°¡¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀǽÄÀÌ Áõ°¡ÇÏ°í °³ÀÎÈµÈ ÀÇ·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. ¶ÇÇÑ, ¸é¿ª±Û·ÎºÒ¸°Àº ´Ù¾çÇÑ Åõ¿© °æ·Î¸¦ ÅëÇØ ½Åü°¡ ´Ù¾çÇÑ °¨¿°°ú ½Î¿ï ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ±× °á°ú, Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ÀÔ¿ø ȯÀÚ¼ö°¡ Áõ°¡Çϰí, À¯Ç༺ÀÇ È®´ë¸¦ ¸·±â À§ÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀÌ ½Ã±ÞÇØÁö°í Àֱ⠶§¹®¿¡ °í¸é¿ª±Û·ÎºÒ¸°Àº °¨¿°Áõ °ü¸®¿¡ È¿°ú ÀǾàǰÀ¸·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ¿©·¯ Á¦¾à ȸ»ç°¡ ½Å°æ Áúȯ Ä¡·á¸¦ À§ÇØ È¿À²¼ºÀ» Çâ»ó½ÃŲ »õ·Î¿î ¸é¿ª±Û·ÎºÒ¸°À» ¹ßÇ¥Çß½À´Ï´Ù. ¿¬±¸°³¹ß(R&D) ÇÁ·ÎÁ§Æ®¿¡ ´ëÇÑ ÀÚ±Ý Á¦°ø Áõ°¡ ¹× ÇコÄɾî ÀÎÇÁ¶ó °³¼±°ú °°Àº ±âŸ ¿äÀε鵵 ÇâÈÄ ¼ö³â°£ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·ç´Â ÁÖ¿ä Áú¹®
- 2023³â ¼¼°è ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå ±Ô¸ð´Â?
- 2024-2032³â ¼¼°è ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
- ¼¼°èÀÇ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
- ¼¼°èÀÇ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
- ¼¼°èÀÇ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀÇ ¿ëµµº° ³»¿ªÀº?
- ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀÇ ³³ÀÔ Çüź° ³»¿ªÀº?
- ¸é¿ª±Û·ÎºÒ¸° ½ÃÀåÀÇ ¼¼°è¿¡¼ ÁÖ¿ä Áö¿ªÀº?
- ¼¼°èÀÇ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå¿¡¼ ÁÖ¿ä ±â¾÷Àº?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý
- Á¶»çÀÇ ¸ñÀû
- ÀÌÇØ°ü°èÀÚ
- µ¥ÀÌÅÍ ¼Ò½º
- ½ÃÀå ÃßÁ¤
- Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ¼Ò°³
Á¦5Àå ¼¼°èÀÇ ¸é¿ª±Û·ÎºÒ¸° ½ÃÀå
- ½ÃÀå °³¿ä
- ½ÃÀå ½ÇÀû
- COVID-19ÀÇ ¿µÇâ
- ½ÃÀå ¿¹Ãø
Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°
Á¦7Àå ½ÃÀå ºÐ¼® : ¿ëµµº°
- Àú°¨¸¶±Û·ÎºÎ¹ÎÇ÷Áõ
- ¸¸¼º ¿°Áõ¼º Å»¼ö¼º ´Ù¹ß½Å°æ¿°(CIDP)
- ¸é¿ª °áÇÌ Áúȯ
- ÁßÁõ±Ù¹«·ÂÁõ
- ±âŸ
Á¦8Àå ½ÃÀå ºÐ¼® : Àü´Þ¾ç½Äº°
- Á¤¸Æ³» Åõ¿©¹ý
- ÇÇÇÏ Åõ¿©¹ý
Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°
- ºÏ¹Ì
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- Àεµ³×½Ã¾Æ
- ±âŸ
- À¯·´
- µ¶ÀÏ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀå µ¿Çâ
- ½ÃÀå ºÐ¼® : ±¹°¡º°
- ½ÃÀå ¿¹Ãø
Á¦10Àå SWOT ºÐ¼®
Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®
Á¦12Àå Porter's Five Forces ºÐ¼®
- °³¿ä
- ±¸¸ÅÀÚÀÇ Çù»ó·Â
- °ø±Þ±â¾÷ÀÇ Çù»ó·Â
- °æÀïµµ
- ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
Á¦13Àå °¡°Ý ºÐ¼®
Á¦14Àå °æÀï ±¸µµ
- ½ÃÀå ±¸Á¶
- ÁÖ¿ä ±â¾÷
- ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
- ADMA Biologics Inc.
- Baxter international Inc.
- Biotest AG
- CSL Limited
- Grifols SA
- Kedrion SpA
- LFB SA
- Octapharma AG
- Sanquin Plasma Products BV
- Takeda Pharmaceutical Company Limited
JHS
The global immunoglobulin market size reached US$ 15.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.
Also known as antibodies, immunoglobulins refer to a class of glycoprotein molecules produced by plasma or white blood cells (WBCs). They are generally present in the serum and cells of the immune system and function as antibodies by explicitly recognizing and binding antigens, such as bacteria or viruses, and aiding in their destruction. Their tests help doctors diagnose immunodeficiencies, allergies, and autoimmune conditions like juvenile idiopathic arthritis, lupus, and celiac disease. At present, different classes of immunoglobulins are available around the world depending on biological features, structure, target specificity, and distribution.
Immunoglobulin Market Trends:
Due to rapid urbanization and hectic schedules, there is a rise in the consumption of fast food among individuals. This, along with sedentary lifestyles and the increasing number of patients with medical conditions like multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders, represents one of the primary factors impelling the growth of the market. Additionally, rising awareness about early diagnosis and the increasing preferences for personalized medicines are contributing to market growth. Moreover, immunoglobulins through a variety of routes of administration help the body fight various infectious diseases. As a result, with the rising number of hospitalized patients with coronavirus disease (COVID-19) and an urgent need for effective therapies to prevent the spread of the pandemic, hyperimmune globulin is utilized as an effective medicine in managing the infection. Apart from this, several pharmaceutical companies are introducing new and advanced immunoglobulins with improved efficiency for the treatment of neurological disorders. Other factors, such as increasing funding for research and development (R&D) projects and the improving healthcare infrastructure are anticipated to propel the market growth further in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunoglobulin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and mode of delivery.
Breakup by Product:
IgG
IgA
IgM
IgE
IgD
Breakup by Application:
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunodeficiency Disease
Myasthenia Gravis
Others
Breakup by Mode of Delivery:
Intravenous Mode of Delivery
Subcutaneous Mode of Delivery
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics Inc., Baxter international Inc., Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB SA, Octapharma AG, Sanquin Plasma Products B.V. and Takeda Pharmaceutical Company Limited.
Key Questions Answered in This Report
- 1. What was the size of the global immunoglobulin market in 2023?
- 2. What is the expected growth rate of the global immunoglobulin market during 2024-2032?
- 3. What are the key factors driving the global immunoglobulin market?
- 4. What has been the impact of COVID-19 on the global immunoglobulin market?
- 5. What is the breakup of the global immunoglobulin market based on the application?
- 6. What is the breakup of the global immunoglobulin market based on the mode of delivery?
- 7. What are the key regions in the global immunoglobulin market?
- 8. Who are the key players/companies in the global immunoglobulin market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Immunoglobulin Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 IgG
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 IgA
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 IgM
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 IgE
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 IgD
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Application
- 7.1 Hypogammaglobulinemia
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Immunodeficiency Disease
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Myasthenia Gravis
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Mode of Delivery
- 8.1 Intravenous Mode of Delivery
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Subcutaneous Mode of Delivery
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 ADMA Biologics Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.2 Baxter international Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Biotest AG
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 CSL Limited
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Grifols S.A
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Kedrion S.p.A
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 LFB SA
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Octapharma AG
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 SWOT Analysis
- 14.3.9 Sanquin Plasma Products B.V.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 Takeda Pharmaceutical Company Limited
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis